Looking to the future of synthetic biology in cell and gene therapies.

Featuring:
Dr. George Church, Professor of Genetics, Harvard Medical School
Dr. Peter Zandstra C.M., Director and Professor, School of Biomedical Engineering, University of British Columbia

Hear from Drs. Church and Zandstra about the promise of the emerging synthetic biology field, looking to the impact developments will have on cell and gene therapies. They discuss how the regenerative medicine ecosystem needs to prepare for the arrival of transformative synthetic biology-based technologies, how equitable distribution can happen, and what those looking to commercialize these technologies will need to consider. The conversation also touches on the ethical considerations synthetic biology raises, asking how we stay on the right track en route to the future of personalized medicine.

Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.